EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
March 30, 2023 07:00 ET
|
Diffusion Pharmaceuticals Inc.
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in...
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
December 16, 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be...
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing
December 05, 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 16:01 ET
|
Diffusion Pharmaceuticals Inc.
Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
October 25, 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 18:48 ET
|
Diffusion Pharmaceuticals Inc.
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
July 26, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...